Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-21
DOI
10.1038/s41416-020-01257-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
- (2020) Fara Brasó-Maristany et al. Nature Communications
- Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
- (2020) Maria Gaibar et al. Journal of Oncology
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
- (2020) Anita Kulukian et al. MOLECULAR CANCER THERAPEUTICS
- Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
- (2019) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib: a Brief Report
- (2019) Gina M. Castellano et al. Journal of Thoracic Oncology
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-positive breast cancer: Current and new therapeutic strategies
- (2018) Santiago Escrivá-de-Romaní et al. BREAST
- The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
- (2018) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
- (2018) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies
- (2018) B. Madhu Krishna et al. Scientific Reports
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
- (2018) Alexandra Canonici et al. INVESTIGATIONAL NEW DRUGS
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
- (2018) Kanika Bajaj Pahuja et al. CANCER CELL
- Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017
- (2018) Joost C.M. Uitdehaag et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
- (2017) Ji-Yeon Kim et al. Oncotarget
- Genomic alterations of ERBB receptors in cancer: clinical implications
- (2017) Rosalin Mishra et al. Oncotarget
- Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
- (2016) Joost C.M. Uitdehaag et al. MOLECULAR CANCER THERAPEUTICS
- The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
- (2016) Courtney Hodges et al. Cold Spring Harbor Perspectives in Medicine
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlating chemical sensitivity and basal gene expression reveals mechanism of action
- (2015) Matthew G Rees et al. Nature Chemical Biology
- Clinical management of breast cancer heterogeneity
- (2015) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
- (2015) Joost C. M. Uitdehaag et al. PLoS One
- A comprehensive transcriptional portrait of human cancer cell lines
- (2014) Christiaan Klijn et al. NATURE BIOTECHNOLOGY
- Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
- (2013) Aisling Pierce et al. CANCER BIOLOGY & THERAPY
- An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity
- (2012) Nicole L Moore et al. ENDOCRINE-RELATED CANCER
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells
- (2011) Yong Zhao et al. CANCER LETTERS
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
- (2009) D D Meira et al. BRITISH JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now